カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の抗ウイルス薬市場2023-2030：タイプ別（ブランド、ジェネリック）、薬剤クラス別、流通チャネル別（病院薬局、小売薬局）、用途別、地域別

【英語タイトル】Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV002）・商品コード：GRV23NOV002
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：180
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

抗ウイルス薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の抗ウイルス薬市場規模は、2023年から2030年にかけて年平均成長率-1.99%を記録し、2030年までに620.5億米ドルに達する見込みです。この背景には、ウイルス性疾患の有病率の上昇と、感染症の蔓延を抑えるための新規治療薬の開発に関連する政府のイニシアチブの高まりがあります。さらに、研究開発への取り組みの増加や、予防接種や併用療法など、最新かつ最新の詳細情報の拡大が、市場の成長を促進すると予測されています。ウイルスのパンデミックが発生する可能性があることから、適切なワクチン接種が行われるまでの間、ウイルスの蔓延を食い止めるために、即座に大規模展開できる直接作用型抗ウイルス薬などの広域抗ウイルス薬の必要性が浮き彫りになっています。抗ウイルス薬のブロックバスター治療薬の登場は、さまざまなウイルス感染症の治療に変革をもたらしました。

ソバルディ（ソホスブビル）、ハーボニー（レディパスビル／ソホスブビル）、エプクローサ（ソホスブビル／ベルパタスビル）などのC型肝炎治療薬は、従来の治療薬に比べて高い治癒率、短い治療期間、少ない副作用を実現し、この分野に革命をもたらしました。これらの薬剤は、C型肝炎の治癒に有効であること、そしてアンメット・メディカル・ニーズに応えるものであることから、ブロックバスターの地位を獲得しました。抗ウイルス薬に対する政府の取り組みには、研究開発への資金提供、承認や緊急使用認可のための規制プロセスの合理化、備えのための戦略的備蓄、効果的な抗ウイルス治療薬の開発を加速し、入手しやすくするための産学機関との連携などがあります。

例えば、2022年5月、国立衛生研究所の一部である国立アレルギー感染症研究所（NIAID）は、パンデミックが懸念される病原体のための9つの抗ウイルス薬発見（AViDD）センターを立ち上げるために約5億7700万米ドルを付与しました。さらに、政府機関と主要企業との協力関係の増加が、新規抗ウイルス薬開発のための研究開発活動の成長を促進すると予想されています。例えば、2021年6月、Merck & Co., Inc.は、COVID-19治療用の治験用抗ウイルス薬であるモルヌピラビルの調達契約を米国政府と締結しました。同契約によると、モルヌピラビルが米国FDAの緊急使用承認または承認を取得した場合、同社は12億米ドルを受領し、約170万コースの薬剤を米国政府に供給することになります。

さらに、市場各社は臨床検査の需要拡大に対応するため、戦略的な取り組みを行っています。大手企業は市場での地位を強化するため、地域企業の買収に乗り出しています。このため、この地域のプレーヤー間の競争は激しいです。同市場のプレーヤーは新製品の開発に注力しています。例えば、2023年6月現在、抗ウイルス薬開発のための臨床試験のフェーズ2、3、4では900件を超える研究が進行中です。さらに、2023年4月には、PharmaMar社がCOVID-19に罹患した免疫抑制患者の治療にプリチデプシンを使用するNereida臨床試験を開始し、スペイン、イタリア、フランス、ポーランド、ハンガリー、ギリシャ、ポルトガルで試験が承認されました。

抗ウイルス薬市場レポートハイライト

- 有効性、安全性、医療当局の承認が実証され、広く採用されていることから、2022年はブランドタイプが市場を席巻しました。

- 薬剤クラス別では、HIV/AIDSなどの慢性疾患の蔓延による効果的な治療薬へのニーズの高まりから、プロテアーゼ阻害薬セグメントが2022年の市場を支配しました。

- 流通チャネル別では、疾病に苦しむ人々の増加、急速な高齢化、入院患者数の増加により、病院薬局セグメントが2022年に最大の市場シェアを占めました。

- 北米は、医療インフラが整備されていること、ウイルス性疾患の有病率が高いこと、治療薬が急速に進歩していることから、同市場において確固たる地位を築いています。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 市場変数・傾向・範囲
第4章 世界の抗ウイルス薬市場：種類別ビジネス分析
第5章 世界の抗ウイルス薬市場：薬剤クラス別ビジネス分析
第6章 世界の抗ウイルス薬市場：流通チャネル別ビジネス分析
第7章 世界の抗ウイルス薬市場：用途別ビジネス分析
第8章 世界の抗ウイルス薬市場：地域別ビジネス分析
第9章 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing prevalence of viral infections
3.4.2. Increasing government initiatives for viral infections
3.4.3. Increasing geriatric population
3.5. Market Restraint Analysis
3.5.1. High cost of treatment
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Antiviral Drugs Market: Type Movement Analysis
4.2. Branded
4.2.1. Branded Market, 2018 – 2030 (USD Million)
4.3. Generics
4.3.1. Generics Market, 2018 – 2030 (USD Million)
Chapter 5. Drug Class Business Analysis
5.1. Antiviral Drugs Market: Drug Class Movement Analysis
5.2. DNA Polymerase Inhibitors
5.2.1. DNA Polymerase Inhibitors Market, 2018 – 2030 (USD Million)
5.3. Reverse Transcriptase Inhibitors
5.3.1. Reverse Transcriptase Inhibitors Market, 2018 – 2030 (USD Million)
5.4. Protease Inhibitors
5.4.1. Protease Inhibitors Market, 2018 – 2030 (USD Million)
5.5. Neuraminidase Inhibitors
5.5.1. Neuraminidase Inhibitors Market, 2018 – 2030 (USD Million)
5.6. Others
5.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Antiviral Drugs Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market, 2018 – 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 – 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market, 2018 – 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Antiviral Drugs Market: Application Movement Analysis
7.2. Influenza
7.2.1. Influenza Market, 2018 – 2030 (USD Million)
7.3. HIV
7.3.1. HIV Market, 2018 – 2030 (USD Million)
7.4. Hepatitis
7.4.1. Hepatitis Market, 2018 – 2030 (USD Million)
7.5. Herpes
7.5.1. Herpes Market, 2018 – 2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Antiviral Drugs Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. U.S. Antiviral drugs Market, 2018 – 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Canada Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. Germany Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.4. UK
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. UK Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. France Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Italy Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Spain Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Denmark Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Sweden Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Reimbursement Scenario
8.3.10.6. Norway Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. Japan Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. China Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. India Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. South Korea Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Australia Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Reimbursement Scenario
8.4.8.6. Thailand Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Brazil Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Mexico Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
8.5.5.6. Argentina Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. South Africa Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. Saudi Arabia Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. UAE Antiviral Drugs Market, 2018 – 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Reimbursement Scenario
8.6.6.6. Kuwait Antiviral Drugs Market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. New Product Launch
9.2.2. Partnership
9.2.3. Acquisition
9.2.4. Collabboration
9.2.5. Funding
9.3. Key Company Market Share Analysis, 2022
9.4. Company Heat Map Analysis
9.5. Company Profiles
9.5.1. F. HOFFMANN-LA ROCHE LTD.
9.5.1.1. Company Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. GSK PLC.
9.5.2.1. Company Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. ABBVIE, INC.
9.5.3.1. Company Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. MERCK & CO., INC.
9.5.4.1. Company Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. JOHNSON & JOHNSON SERVICES, INC.
9.5.5.1. Company Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. BRISTOL-MYERS SQUIBB COMPANY
9.5.6.1. Company Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. CIPLA INC.
9.5.7.1. Company Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. AUROBINDO PHARMA
9.5.8.1. Company Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. DR. REDDY’S LABORATORIES LTD.
9.5.9.1. Company Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 Global Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 3 Global Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 4 Global Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 Global Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 6 Global Antiviral Drugs Market, by Region, 2018 - 2030 (USD Million)
Table 7 North America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 8 North America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 9 North America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 10 North America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 North America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 12 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 13 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 14 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 15 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 16 Canada Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 17 Canada Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Canada Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Canada Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 20 Europe Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 21 Europe Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 22 Europe Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 23 Europe Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 Europe Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 25 Germany Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 26 Germany Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Germany Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Germany Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 29 UK Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 30 UK Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 31 UK Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 UK Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 33 France Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 34 France Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 35 France Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 France Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 37 Italy Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 38 Italy Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Italy Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Italy Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 41 Spain Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 42 Spain Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 43 Spain Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Spain Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 45 Denmark Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 46 Denmark Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 47 Denmark Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Denmark Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 49 Sweden Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 50 Sweden Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 Sweden Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Sweden Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 53 Norway Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 54 Norway Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 55 Norway Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Norway Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 62 China Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 63 China Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 64 China Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 China Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 66 Japan Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 67 Japan Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 68 Japan Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Japan Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 70 India Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 71 India Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 72 India Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 India Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 74 South Korea Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 75 South Korea Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 76 South Korea Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 South Korea Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 78 Australia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 79 Australia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 80 Australia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 81 Australia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 82 Thailand Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 83 Thailand Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 84 Thailand Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 85 Thailand Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 86 Latin America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 87 Latin America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 88 Latin America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 89 Latin America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 90 Latin America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 91 Brazil Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 92 Brazil Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 93 Brazil Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 94 Brazil Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 95 Mexico Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 96 Mexico Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 97 Mexico Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 98 Mexico Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 99 Argentina Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 100 Argentina Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 101 Argentina Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 102 Argentina Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 107 South Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 108 South Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 109 South Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 110 South Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 111 Saudi Arabia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 115 UAE Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 116 UAE Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 117 UAE Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 118 UAE Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 119 Kuwait Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 120 Kuwait Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 121 Kuwait Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 122 Kuwait Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain - Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Antiviral Drugs Market Segmentation
Fig. 8 Market Snapshot, 2022
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
Fig. 16 Global Antiviral Drugs Market: Type Movement Analysis
Fig. 17 Global Antiviral Drugs Market, by Branded, 2018 - 2030 (USD Million)
Fig. 18 Global Antiviral Drugs Market, by Generics, 2018 - 2030 (USD Million)
Fig. 19 Global Antiviral Drugs Market: Drug Class Movement Analysis
Fig. 20 Global Antiviral Drugs Market, by DNA Polymerase Inhibitors, 2018 - 2030 (USD Million)
Fig. 21 Global Antiviral Drugs Market, by Reverse Transcriptase Inhibitors, 2018 - 2030 (USD Million)
Fig. 22 Global Antiviral Drugs Market, by Protease Inhibitors, 2018 - 2030 (USD Million)
Fig. 23 Global Antiviral Drugs Market, by Neuraminidase Inhibitors, 2018 - 2030 (USD Million)
Fig. 24 Global Antiviral Drugs Market, by Others, 2018 - 2030 (USD Million)
Fig. 25 Global Antiviral Drugs Market: Distribution Channel Movement Analysis
Fig. 26 Global Antiviral Drugs Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
Fig. 27 Global Antiviral Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
Fig. 28 Global Antiviral Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
Fig. 29 Regional Marketplace: Key Takeaways
Fig. 30 Regional Outlook, 2022 & 2030
Fig. 31 Global Antiviral Drugs Market: Region Movement Analysis
Fig. 32 North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 33 U.S. Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 34 Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 35 Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 36 Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 37 UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 38 France Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 39 Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 40 Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 41 Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 42 Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 43 Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 45 Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 46 China Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 47 India Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 48 Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 49 South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 50 Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 51 Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 52 Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 53 Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 54 Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 56 South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 58 UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 59 Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)

★調査レポート[世界の抗ウイルス薬市場2023-2030：タイプ別（ブランド、ジェネリック）、薬剤クラス別、流通チャネル別（病院薬局、小売薬局）、用途別、地域別] (コード：GRV23NOV002)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗ウイルス薬市場2023-2030：タイプ別（ブランド、ジェネリック）、薬剤クラス別、流通チャネル別（病院薬局、小売薬局）、用途別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のフィナステリド市場2023-2030：種類別（ブランド、ジェネリック）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局）、用途別（前立腺肥大症（BPH）、男性型脱毛症）、地域別
  • 世界の婦人科用治療薬市場（2023-2033)：疾患別（婦人科系がん、避妊、女性不妊症、更年期障害、多嚢胞性卵巣症候群（PCOS）、その他）、治療薬別（非ホルモン治療薬、ホルモン治療薬）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、種類別（ジェネリック、ブランド）、地域別
  • 世界の抗生物質市場2024-2030：作用機序別（細胞壁合成阻害剤、RNA合成阻害剤）、薬剤クラス別（ペニシリン、セファロスポリン）、種類別（ブランド、ジェネリック）
  • 世界のアスペルギルス症治療市場2023-2030：タイプ別（アレルギー性、慢性、侵襲性）、薬剤クラス別（抗真菌薬）、投与経路別、流通チャネル別、地域別
  • 世界の急性呼吸窮迫症候群（ARDS）治療薬市場2023-2030：薬剤クラス別（血管収縮薬、気管支拡張薬、ステロイド、抗生物質、その他）、投与経路別（経口、注射、吸入）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、地域別
  • 世界の白斑治療市場2023-2030：種類別（セグメンタル、非セグメンタル）、流通チャネル別（ドラッグストア・小売薬局、オンラインプロバイダー、病院薬局）、薬剤クラス別（副腎皮質ステロイド、カルシニューリン阻害剤、その他）、地域別
  • 世界のヒト成長ホルモン市場2023-2030：流通チャネル別（病院薬局、小売薬局）、用途別、製品別、地域別
  • 世界のインクレチン系薬剤市場2023年-2032年：薬剤クラス別（GLP-1受容体作動薬、DPP-4阻害薬）、投与経路別（非経口、経口）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 世界の糖尿病性腎症市場2022年-2031年：薬剤クラス別（アンジオテンシン変換酵素阻害薬、アンジオテンシン受容体拮抗薬、カルシウム拮抗薬、利尿薬、レニン阻害薬、その他）、種類別（1型糖尿病、2型糖尿病）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局）
  • 世界のメチシリン耐性黄色ブドウ球菌治療薬市場2023-2030：薬剤クラス別（リポペプチド、オキサゾリジノン、セファロスポリン、テトラサイクリン、葉酸拮抗薬、その他薬剤クラス）、投与経路別（経口投与、非経口投与）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆